Key statistics
On Tuesday, Halozyme Therapeutics Inc (RV7:STU) closed at 67.30, -2.27% below its 52-week high of 68.86, set on Feb 09, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 67.24 |
|---|---|
| High | 68.46 |
| Low | 67.24 |
| Bid | 67.36 |
| Offer | 67.54 |
| Previous close | 67.56 |
| Average volume | 230.00 |
|---|---|
| Shares outstanding | 117.60m |
| Free float | 116.26m |
| P/E (TTM) | 16.92 |
| Market cap | 9.46bn USD |
| EPS (TTM) | 4.76 USD |
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Press releases
- Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
- Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
- Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update
- Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
- Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
- U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
- Jim Lang Elected to Halozyme's Board of Directors
- Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
- Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
- Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
More ▼
